Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Steris (2TG) Price & Analysis

2TG Stock Chart & Stats

€203.40-€4.60(-2.21%)
At close: 4:00 PM EDT
EUR 190EUR 2003 Aug17 Aug27 Aug15 Sep1 Oct15 Oct23 Oct
Day’s Range
EUR 205.80 - EUR 207.40
52-Week Range
EUR 170.40 - EUR 236.00
Previous Close
EUR 208.00
Volume
80
Average Volume (3M)
8
Market Cap
EUR 19.76B
Enterprise Value
EUR 22.19B
Total Cash (Recent Filing)
EUR 482.30M
Total Debt (Recent Filing)
EUR 2.04B
Price to Earnings (P/E)
27.7
Beta
0.31
Next Earnings
Nov 05, 2026
EPS Estimate
2.39
Next Dividend Ex-Date
N/A
Dividend Yield
1.09%

Bulls Say, Bears Say

Bulls Say

Recurring Revenue Model

STERIS combines capital equipment with recurring consumables, service contracts, lifecycle support, and outsourced sterilization. This installed-base model can deepen customer relationships, support predictable demand, and make revenue more resilient than a business dependent only on periodic equipment sales.

Healthcare Growth And Margin Expansion

Recent growth was accompanied by meaningful gross- and EBIT-margin expansion, indicating that pricing, productivity, mix, and cost discipline are translating into operating leverage. That combination strengthens earnings quality and supports continued investment across STERIS’s healthcare and life-sciences franchises.

Conservative Balance Sheet

Very low reported leverage gives STERIS substantial financial flexibility to fund operations, invest in capacity, and manage industry volatility. Improved returns on equity also suggest that the company is generating stronger earnings from its capital base, reinforcing balance-sheet quality over the medium term.

Bears Say

Debt-Financed Xodus Acquisition

The Xodus transaction represents a major capital deployment and is expected to increase leverage from STERIS’s currently conservative position. Integration, financing, and execution requirements could reduce financial flexibility before the acquired specialty surgical portfolio produces its expected strategic benefits.

Heavy Multi-Year Investment And Restructuring

The chemistry consolidation requires substantial capital spending across fiscal 2027-2029 while also creating sizable restructuring costs. These commitments can suppress free cash flow and raise execution demands in the medium term, even if the new capacity ultimately improves efficiency and supports growth.

Life Sciences Margin Pressure

Margin compression in Life Sciences indicates that pricing and volume gains are not currently fully offsetting productivity challenges and inflation. If these pressures persist, they could dilute consolidated profitability and limit the earnings benefit from continued revenue growth in an important operating segment.

Steris News

2TG FAQ

What was Steris’s price range in the past 12 months?
Steris lowest stock price was €170.40 and its highest was €236.00 in the past 12 months.
What is Steris’s market cap?
Steris’s market cap is €19.76B.
When is Steris’s upcoming earnings report date?
Steris’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were Steris’s earnings last quarter?
Steris released its earnings results on Aug 05, 2026. The company reported €2.311 earnings per share for the quarter, beating the consensus estimate of €2.227 by €0.085.
Is Steris overvalued?
According to Wall Street analysts Steris’s price is currently Undervalued.
Does Steris pay dividends?
Steris does not currently pay dividends.
What is Steris’s EPS estimate?
Steris’s EPS estimate is 2.39.
How many shares outstanding does Steris have?
Steris has 97,500,110 shares outstanding.
What happened to Steris’s price movement after its last earnings report?
Steris reported an EPS of €2.311 in its last earnings report, beating expectations of €2.227. Following the earnings report the stock price went down -0.298%.
Which hedge fund is a major shareholder of Steris?
Currently, no hedge funds are holding shares in DE:2TG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology